The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular subtypes and clinical outcomes to initial systemic treatment in patients with small cell lung cancer.
 
Wei-Chu Victoria Lai
Consulting or Advisory Role - G1 Therapeutics; PharmaMar
Research Funding - Amgen (Inst); Daiichi Sankyo (Inst)
 
Jacklynn V. Egger
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Allison L. Richards
No Relationships to Disclose
 
Amanda Beras
No Relationships to Disclose
 
Marina K. Baine
No Relationships to Disclose
 
Min-Shu Hsieh
No Relationships to Disclose
 
Jason C. Chang
No Relationships to Disclose
 
Natasha Rekhtman
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Pfizer
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Triparna Sen
No Relationships to Disclose
 
John T. Poirier
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bridge Medicines; Celgene; Daiichi Sankyo; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)